VivoSeq
Oncology

Advanced Solid Tumors Cancer

8

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Advanced Solid Tumors Cancer is an early-stage landscape with 8 programs across 8 companies. The most active players are Genfleet Therapeutics (Shanghai) Inc., Imclone, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Genfleet Therapeutics (Shanghai) Inc.

1 program

PreclinicalI

Imclone

1 program

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalG

Glaxo Dba Glaxosmithkline

1 program

PreclinicalPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Preclinical·NCT07678593·222 enrolled
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Recruiting·EElephas·N/A·NCT07327489·2,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)